TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A systematic review and meta-analysis covering nearly 16 million people found ADHD was associated with a 71% higher rate of all-cause mortality, as well as elevated rates of suicide, injury and natural-cause mortality. ADHD medication use was associated with lower all-cause mortality, but that analysis included only three studies and cannot establish that medication caused the difference.
A systematic review and meta-analysis of 19 studies involving 15,920,970 people found that ADHD was associated with a 71% higher rate of all-cause mortality than in comparison groups. The analysis, reported by Joshua Stott of University College London and colleagues in JAMA Network Open, also found higher rates of suicide, injury and natural-cause mortality, while a lower mortality association among people taking ADHD medication was based on only three studies.
The researchers reported an all-cause mortality hazard ratio of 1.71 for people with ADHD (95% confidence interval, 1.31 to 2.24). Hazard ratios were also elevated for suicide (1.89), intentional or unintentional injury (1.55), and natural causes (1.27). These are relative associations across the studies, not predictions of an individual person’s lifespan or absolute chances of dying.
For people with ADHD who used medication, the pooled analysis found a lower all-cause mortality association, with a hazard ratio of 0.75 (95% confidence interval, 0.64 to 0.87). The authors cautioned that this result rested on three studies and could reflect differences between treated and untreated groups, rather than a medication effect. The review combined studies with varied populations and ways of identifying ADHD, including clinical diagnoses, self-identification, trait measures and genetic risk scores.
Stott and colleagues searched peer-reviewed research available through July 2025. Twelve studies contributed data to the five meta-analyses. Most participants were male, at 63.9%, and the authors reported substantial variation across several analyses. They said the included studies consistently showed higher mortality in ADHD groups, though the size of the association differed.
Mortality Patterns Point to Care Gaps
The findings add population-level evidence that people with ADHD face elevated mortality rates across several causes. They do not show that ADHD directly causes those deaths, but they highlight potential health and safety needs that may be missed when the condition is not identified or when associated needs go untreated.
The authors discussed several possible pathways, not as causes proven by this analysis but as factors that could contribute. Impulsivity, emotional dysregulation and risk-taking may be associated with injury; co-occurring depression may affect suicide risk; and smoking, alcohol use, cardiovascular or metabolic conditions, and barriers to health care may contribute to natural-cause outcomes.
Stott told MedPage Today that the results do not mean everyone with ADHD will die young or that elevated mortality is inherent or unchangeable. He said they support access to accurate diagnosis and treatment. That distinction matters: the study reports group-level associations, not an individual prognosis or a treatment recommendation.
As an affiliate, we earn on qualifying purchases.
Late ADHD Diagnosis in Adults
ADHD can go unrecognized into adulthood, according to Jeffrey Newcorn, a Mount Sinai psychiatrist who was not involved in the review. He told MedPage Today that diagnoses are often made late and that many diagnosed adults do not receive treatment. The review’s authors also noted that diagnosis rates may lag behind prevalence, particularly among older adults.
The U.S. Centers for Disease Control and Prevention estimates that 15 million U.S. adults—about 6%—have ADHD; nearly one in three take stimulant medication, according to the supplied CDC figures. The agency estimates that 7 million children ages 3 to 17, or 11.7%, have an ADHD diagnosis based on a national survey of parents.
Earlier studies had also reported higher mortality among people with ADHD, and some had suggested a life-expectancy gap. The new review brought together research across age groups and countries. Differences in diagnostic criteria, access to care and participant characteristics limit how directly the pooled estimates can be applied to any one population.
“These findings do not suggest that everyone with ADHD will die young, nor do they suggest that increased mortality is impossible to change or inherent to ADHD.”
— Joshua Stott, University College London, speaking to MedPage Today
Medication Findings Need Caution
The review cannot establish that ADHD itself caused the higher mortality rates, or that medication reduced them. The medication estimate came from only three studies, and people who receive treatment may differ from those who do not in health-care access, socioeconomic circumstances, symptom severity, adherence and other psychiatric conditions. The authors specifically warned about residual confounding and confounding by indication.
There was also considerable heterogeneity in the all-cause, suicide and injury analyses, meaning results varied in magnitude across studies. The researchers noted that studies differed in populations and diagnostic approaches, and many had gender imbalances. The findings do not provide an absolute mortality rate, identify which interventions would lower risk, or show whether the associations apply equally across age groups and settings.
Further Studies Must Clarify Risk
The review establishes a basis for further research, but it does not report a scheduled follow-up study or a specific policy change. Future studies would need to examine why mortality estimates differ across populations and whether diagnosis, treatment access or particular health and social factors account for some of the association.
More evidence is also needed to test the medication finding using larger, well-designed comparisons that address differences between treated and untreated people. Until then, the authors’ results are best read as an association that supports attention to diagnosis and health needs—not proof that medication prevents deaths.
Key Questions
What did the review find about ADHD and mortality?
Across the included studies, ADHD was associated with a 71% higher rate of all-cause mortality. The review also found elevated relative rates for suicide, injury and natural-cause mortality. These estimates describe associations among groups, not an individual’s personal risk.
Does the study show that ADHD causes early death?
No. The research pooled observational studies and found associations; it does not establish that ADHD caused the deaths. The authors discussed possible contributing pathways, but the review did not prove those mechanisms.
Did ADHD medication lower the risk of death?
Medication use was associated with a lower all-cause mortality rate in the pooled analysis, but the estimate came from just three studies. Differences between people who did and did not receive medication could explain some or all of the association; the result does not prove medication prevents deaths.
Who was included in the research?
The review included 19 studies and 15,920,970 participants across age groups. ADHD was identified in different ways across studies, and 63.9% of participants were male.
What remains uncertain?
The review does not establish causes, individual absolute risk, or whether the findings apply equally across populations. Variation in study methods and the small number of medication studies also limit conclusions about treatment and mortality.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
